Coloplast A/S revised earnings guidance for the fiscal year 2023/24. For the year, the company the organic revenue growth is still expected to be around 8%. Reported revenue growth in DKK is now expected to be 10-11%, from previously around 11%, and includes negative impact of 1-2%-points from currencies, from previously around 1%-point.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
824.8 DKK | -0.31% | -2.30% | +6.84% |
May. 15 | COLOPLAST : Multiple silver linings in spite of a soft Q2 24 | |
May. 07 | European shares hit one-month high as earnings take centre stage | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.84% | 26.97B | |
-40.08% | 2.67B | |
-19.95% | 2.4B | |
+16.30% | 2.28B | |
+7.28% | 2.24B | |
+16.67% | 1.79B | |
-13.56% | 1.82B | |
+18.92% | 1.26B | |
+20.00% | 1.2B | |
-5.27% | 1.21B |
- Stock Market
- Equities
- COLO B Stock
- News Coloplast A/S
- Coloplast A/S Revises Earnings Guidance for the Fiscal Year 2023/24